BB-K 122: in vitro and in vivo activity against ocular pathogens.
BB-K 122 is a new aminoglycoside antibiotic and an analogue of amikacin. This study evaluated the in vitro and in vivo activity of BB-K 122 and gentamicin against important ocular pathogens. BB-K 122 and gentamicin demonstrated generally equivalent in vitro antibacterial activity, except that gentamicin was more active against Streptococcus sp. BB-K 122 showed significant in vitro activity against important ophthalmic pathogens, including Pseudomonas aeruginosa, Staphylococcus aureus, Acinetobacter calcoaceticus, and species of Klebsiella, Escherichia, Proteus, Haemophilus, and Moraxella. Solutions of BB-K 122 (1%) and gentamicin sulfate (0.3%) were compared in an experimentally induced rabbit keratoconjunctivitis model. Rabbit eyes infected with P. aeruginosa or S. pneumoniae were treated with one of the two antibiotic formulations and evaluated after 24 h. A topical formulation of 1% BB-K 122 was at least as effective as gentamicin sulfate (0.3%) solution against these infections.
D000583:Amikacin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D005128:Eye Diseases / Q000188:drug therapy*; D005260:Female; D066298:In Vitro Techniques; D007612:Kanamycin / Q000031:analogs & derivatives*; D008297:Male; D011008:Pneumococcal Infections / Q000188:drug therapy; D011552:Pseudomonas Infections / Q000188:drug therapy; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D011817:Rabbits; D013211:Staphylococcus aureus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects
D000900:Anti-Bacterial Agents; D007612:Kanamycin; C013452:1-N-acylkanamycin B; D000583:Amikacin